Previous
Previous

Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.

Next
Next

JPM 2026: Aurora Therapeutics’ Edward Kaye on Scalable Personalized Gene Editing